# Massimo Mannelli

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 189 papers | 18,954 citations | 20759 60 h-index | 12910 131 g-index |
| 197 all docs | 197 docs citations | 197 times ranked | 11984 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | SDHB and SDHD silenced pheochromocytoma spheroids respond differently to tumour microenvironment and their aggressiveness is inhibited by impairing stroma metabolism. Molecular and Cellular Endocrinology, 2022, 547, 111594. | 1.6 | 5 |
| 2 | Metformin Treatment Induces Different Response in Pheochromocytoma/Paraganglioma Tumour Cells and in Primary Fibroblasts. Cancers, 2022, 14, 3471. | 1.7 | 4 |
| 3 | Adrenocortical carcinoma: current treatment options. Current Opinion in Oncology, 2021, 33, 16-22. | 1.1 | 15 |
| 4 | Functional significance of germline EPAS1 variants. Endocrine-Related Cancer, 2021, 28, 97-109. | 1.6 | 6 |
| 5 | International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nature Reviews Endocrinology, 2021, 17, 435-444. | 4.3 | 80 |
| 6 | Circulating Fascin 1 as a Promising Prognostic Marker in Adrenocortical Cancer. Frontiers in Endocrinology, 2021, 12, 698862. | 1.5 | 5 |
| 7 | Analysis of Telomere Maintenance Related Genes Reveals NOP10 as a New Metastatic-Risk Marker in Pheochromocytoma/Paraganglioma. Cancers, 2021, 13, 4758. | 1.7 | 14 |
| 8 | Stimulated Expression of CXCL12 in Adrenocortical Carcinoma by the PPARgamma Ligand Rosiglitazone Impairs Cancer Progression. Journal of Personalized Medicine, 2021, 11, 1097. | 1.1 | 6 |
| 9 | A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy. Cancers, 2021, 13, 5831. | 1.7 | 5 |
| 10 | Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes and Endocrinology,the, 2020, 8, 773-781. | 5.5 | 129 |
| 11 | SDHx and Non-Chromaffin Tumors: A Mediastinal Germ Cell Tumor Occurring in a Young Man with Germline SDHB Mutation. Medicina (Lithuania), 2020, 56, 561. | 0.8 | 3 |
| 12 | Prognostic and Monitoring Value of Circulating Tumor Cells in Adrenocortical Carcinoma: A Preliminary Monocentric Study. Cancers, 2020, 12, 3176. | 1.7 | 10 |
| 13 | The Role of Metabolic Changes in Shaping the Fate of Cancer-Associated Adipose Stem Cells. Frontiers in Cell and Developmental Biology, 2020, 8, 332. | 1.8 | 10 |
| 14 | Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas. Journal of Pathology, 2020, 251, 378-387. | 2.1 | 23 |
| 15 | Germline Mutation in KIF1BÎ² Gene Associated with Loss of Heterozygosity: Usefulness of Next-Generation Sequencing in the Genetic Screening of Patients with Pheochromocytoma. International Journal of Endocrinology, 2020, 2020, 1-8. | 0.6 | 2 |
| 16 | Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. Journal of Hypertension, 2020, 38, 1443-1456. | 0.3 | 190 |
| 17 | Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study. Cancers, 2020, 12, 359. | 1.7 | 23 |
| 18 | Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma. Genetics in Medicine, 2019, 21, 705-717. | 1.1 | 60 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Heat Shock Protein 90 as a Prognostic Marker and Therapeutic Target for Adrenocortical Carcinoma. Frontiers in Endocrinology, 2019, 10, 487. | 1.5 | 14 |
| 20 | Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma. JAMA Oncology, 2019, 5, 1440. | 3.4 | 57 |
| 21 | Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma. Theranostics, 2019, 9, 4946-4958. | 4.6 | 54 |
| 22 | Pheochromocytomas and Paragangliomas as Causes of Endocrine Hypertension. Frontiers in Endocrinology, 2019, 10, 333. | 1.5 | 18 |
| 23 | Malignant Pheochromocytoma. , 2019, , 460-468. | | 0 |
| 24 | Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2367-2374. | 1.8 | 103 |
| 25 | The Adipose Stem Cell as a Novel Metabolic Actor in Adrenocortical Carcinoma Progression: Evidence from an In Vitro Tumor Microenvironment Crosstalk Model. Cancers, 2019, 11, 1931. | 1.7 | 17 |
| 26 | CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 312-318. | 1.8 | 96 |
| 27 | Fascin-1 Is a Novel Prognostic Biomarker Associated With Tumor Invasiveness in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1712-1724. | 1.8 | 28 |
| 28 | Human fetal adrenal cells retain ageâ€•related stemâ€•and endocrineâ€‘differentiation potential in culture. FASEB Journal, 2019, 33, 2263-2277. | 0.2 | 34 |
| 29 | Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term. Hypertension, 2018, 71, 585-591. | 1.3 | 149 |
| 30 | DIAGNOSIS of ENDOCRINE DISEASE: SDHx mutations: beyond pheochromocytomas and paragangliomas. European Journal of Endocrinology, 2018, 178, R11-R17. | 1.9 | 22 |
| 31 | A case of malignant insulinoma responsive to somatostatin analogs treatment. BMC Endocrine Disorders, 2018, 18, 98. | 0.9 | 8 |
| 32 | Primary fibroblast co-culture stimulates growth and metabolism in Sdhb-impaired mouse pheochromocytoma MTT cells. Cell and Tissue Research, 2018, 374, 473-485. | 1.5 | 23 |
| 33 | Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. Genetics in Medicine, 2018, 20, 1652-1662. | 1.1 | 45 |
| 34 | The Endocrine Regulation of Blood Pressure. Endocrinology, 2018, , 611-625. | 0.1 | 0 |
| 35 | Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell, 2017, 31, 181-193. | 7.7 | 532 |
| 36 | Prognostic factors in ectopic Cushingâ€™s syndrome due to neuroendocrine tumors: a multicenter study. European Journal of Endocrinology, 2017, 176, 453-461. | 1.9 | 66 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1358-1365. | 1.8 | 108 |
| 38 | Quantitative Value of Aldosteroneâ€Renin Ratio for Detection of Aldosteroneâ€Producing Adenoma: The Aldosteroneâ€Renin Ratio for Primary Aldosteronism (AQUARR) Study. Journal of the American Heart Association, 2017, 6, . | 1.6 | 64 |
| 39 | The mTORC1 Complex Is Significantly Overactivated in <b><i>SDHX</i></b>-Mutated Paragangliomas. Neuroendocrinology, 2017, 105, 384-393. | 1.2 | 10 |
| 40 | The microenvironment induces collective migration in SDHB-silenced mouse pheochromocytoma spheroids. Endocrine-Related Cancer, 2017, 24, 555-564. | 1.6 | 26 |
| 41 | Evaluation and diagnostic potential of circulating extracellular vesicle-associated microRNAs in adrenocortical tumors. Scientific Reports, 2017, 7, 5474. | 1.6 | 51 |
| 42 | Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3491-3498. | 1.8 | 33 |
| 43 | PheoSeq. Journal of Molecular Diagnostics, 2017, 19, 575-588. | 1.2 | 63 |
| 44 | Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. Nature Reviews Endocrinology, 2017, 13, 233-247. | 4.3 | 198 |
| 45 | Sunitinib in the therapy of malignant paragangliomas: report on the efficacy in a SDHB mutation carrier and review of the literature. Archives of Endocrinology and Metabolism, 2017, 61, 90-97. | 0.3 | 15 |
| 46 | New insights in the clinical and translational relevance of miR483-5p in adrenocortical cancer. Oncotarget, 2017, 8, 65525-65533. | 0.8 | 28 |
| 47 | Potential Pitfalls of SDH Immunohistochemical Detection in Paragangliomas and Phaeochromocytomas Harbouring Germline SDHx Gene Mutation. Anticancer Research, 2017, 37, 805-812. | 0.5 | 26 |
| 48 | Commentary. Clinical Chemistry, 2016, 62, 929-929. | 1.5 | 0 |
| 49 | DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. Journal of Clinical Endocrinology and Metabolism, 2016, 102, jc.2016-3205. | 1.8 | 44 |
| 50 | Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3526-3538. | 1.8 | 65 |
| 51 | Epigenetic Mutation of the Succinate Dehydrogenase C Promoter in a Patient With Two Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 359-363. | 1.8 | 42 |
| 52 | Metformin as a new anti-cancer drug in adrenocortical carcinoma. Oncotarget, 2016, 7, 49636-49648. | 0.8 | 37 |
| 53 | The Endocrine Regulation of Blood Pressure. Endocrinology, 2016, , 1-15. | 0.1 | 0 |
| 54 | SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). Modern Pathology, 2015, 28, 807-821. | 2.9 | 176 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Immunohistochemical expression of stem cell markers in pheochromocytomas/paragangliomas is associated with SDHx mutations. European Journal of Endocrinology, 2015, 173, 43-52. | 1.9 | 17 |
| 56 | Role of microenvironment on neuroblastoma SK-N-AS SDHB-silenced cell metabolism and function. Endocrine-Related Cancer, 2015, 22, 409-417. | 1.6 | 23 |
| 57 | 15 YEARS OF PARAGANGLIOMA: Metabolism and pheochromocytoma/paraganglioma. Endocrine-Related Cancer, 2015, 22, T83-T90. | 1.6 | 9 |
| 58 | Functional and in silico assessment of MAX variants of unknown significance. Journal of Molecular Medicine, 2015, 93, 1247-1255. | 1.7 | 25 |
| 59 | DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers. Clinical Cancer Research, 2015, 21, 3020-3030. | 3.2 | 53 |
| 60 | Cushingâ€™s syndrome in pregnancy. Gynecological Endocrinology, 2015, 31, 102-104. | 0.7 | 16 |
| 61 | Prognostic factors in stage IIIâ€“IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Annals of Oncology, 2015, 26, 2119-2125. | 0.6 | 196 |
| 62 | Rare diseases in clinical endocrinology: a taxonomic classification system. Journal of Endocrinological Investigation, 2015, 38, 193-259. | 1.8 | 11 |
| 63 | 2D-DIGE proteomic analysis identifies new potential therapeutic targets for adrenocortical carcinoma. Oncotarget, 2015, 6, 5695-5706. | 0.8 | 28 |
| 64 | Oncogenic features of the bone morphogenic protein 7 (BMP7) in pheochromocytoma. Oncotarget, 2015, 6, 39111-39126. | 0.8 | 15 |
| 65 | Novel Somatic Mutations in the Catalytic Subunit of the Protein Kinase A as a Cause of Adrenal Cushing's Syndrome: A European Multicentric Study. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2093-E2100. | 1.8 | 92 |
| 66 | Krebs Cycle Metabolite Profiling for Identification and Stratification of Pheochromocytomas/Paragangliomas due to Succinate Dehydrogenase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3903-3911. | 1.8 | 111 |
| 67 | Pitfalls in Genetic Analysis of Pheochromocytomas/Paragangliomasâ€”Case Report. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2321-2326. | 1.8 | 8 |
| 68 | H-RAS Mutations Are Restricted to Sporadic Pheochromocytomas Lacking Specific Clinical or Pathological Features: Data From a Multi-Institutional Series. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1376-E1380. | 1.8 | 42 |
| 69 | Analysis of circulating microRNAs in adrenocortical tumors. Laboratory Investigation, 2014, 94, 331-339. | 1.7 | 98 |
| 70 | Patient affected by neurofibromatosis type 1 and thyroid C-cell hyperplasia harboring pathogenic germ-line mutations in both NF1 and RET genes. Gene, 2014, 536, 332-335. | 1.0 | 21 |
| 71 | Opposing effects of HIF1Î± and HIF2Î± on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYCâ€associated factor X. International Journal of Cancer, 2014, 135, 2054-2064. | 2.3 | 72 |
| 72 | Integrated genomic characterization of adrenocortical carcinoma. Nature Genetics, 2014, 46, 607-612. | 9.4 | 560 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Succinate Dehydrogenase Subunit B Mutations Modify Human Neuroblastoma Cell Metabolism and Proliferation. Hormones and Cancer, 2014, 5, 174-184. | 4.9 | 20 |
| 74 | Dissecting the Origin of Inducible Brown Fat in Adult Humans Through a Novel Adipose Stem Cell Model from Adipose Tissue Surrounding Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1903-E1912. | 1.8 | 19 |
| 75 | Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. Lancet Oncology, The, 2014, 15, 648-655. | 5.1 | 137 |
| 76 | Detection of circulating tumor cells in adrenocortical neoplasms. Pathology, 2014, 46, S13-S14. | 0.3 | 0 |
| 77 | Integrative genetic, epigenetic and pathological analysis of paraganglioma reveals complex dysregulation of NOTCH signaling. Acta Neuropathologica, 2013, 126, 575-594. | 3.9 | 27 |
| 78 | Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5Î±-Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 161-171. | 1.8 | 131 |
| 79 | Diagnosis and Clinical Pictures. , 2013, , 35-53. | | 1 |
| 80 | Feasibility and safety of minimalâ€incision thyroidectomy for Graves' disease: A prospective, singleâ€center study. Head and Neck, 2013, 35, 1345-1348. | 0.9 | 5 |
| 81 | Detection of Circulating Tumor Cells in Patients With Adrenocortical Carcinoma: A Monocentric Preliminary Study. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3731-3738. | 1.8 | 36 |
| 82 | Yeast model for evaluating the pathogenic significance of SDHB, SDHC and SDHD mutations in PHEO-PGL syndrome. Human Molecular Genetics, 2013, 22, 804-815. | 1.4 | 25 |
| 83 | The Reticulin Algorithm for Adrenocortical Tumor Diagnosis. American Journal of Surgical Pathology, 2013, 37, 1433-1440. | 2.1 | 75 |
| 84 | Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Human Molecular Genetics, 2013, 22, 2169-2176. | 1.4 | 142 |
| 85 | Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells. Endocrine-Related Cancer, 2013, 20, 537-550. | 1.6 | 64 |
| 86 | Genetic-clinical profile of subjects with apparently sporadic extra-adrenal paragangliomas. Frontiers in Endocrinology, 2012, 3, 65. | 1.5 | 3 |
| 87 | Mitochondrial function and content in pheochromocytoma/paraganglioma of succinate dehydrogenase mutation carriers. Endocrine-Related Cancer, 2012, 19, 261-269. | 1.6 | 23 |
| 88 | Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients. Endocrine-Related Cancer, 2012, 19, 149-155. | 1.6 | 71 |
| 89 | Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney International, 2012, 82, 1215-1222. | 2.6 | 35 |
| 90 | Perioperative Management of Pheochromocytoma/Paraganglioma: Is There a State of the Art?. Hormone and Metabolic Research, 2012, 44, 373-378. | 0.7 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2012, 18, 2828-2837. | 3.2 | 277 |
| 92 | Subclinical phaeochromocytoma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 507-515. | 2.2 | 76 |
| 93 | Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. European Journal of Cancer, 2012, 48, 1739-1749. | 1.3 | 304 |
| 94 | Updated and New Perspectives on Diagnosis, Prognosis, and Therapy of Malignant Pheochromocytoma/Paraganglioma. Journal of Oncology, 2012, 2012, 1-10. | 0.6 | 106 |
| 95 | Xenograft models for preclinical drug testing: Implications for adrenocortical cancer. Molecular and Cellular Endocrinology, 2012, 351, 71-77. | 1.6 | 20 |
| 96 | Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nature Genetics, 2011, 43, 663-667. | 9.4 | 478 |
| 97 | Measurements of Plasma Methoxytyramine, Normetanephrine, and Metanephrine as Discriminators of Different Hereditary Forms of Pheochromocytoma. Clinical Chemistry, 2011, 57, 411-420. | 1.5 | 282 |
| 98 | Age at Diagnosis of Pheochromocytoma Differs According to Catecholamine Phenotype and Tumor Location. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 375-384. | 1.8 | 90 |
| 99 | Incidental and Metastatic Adrenal Masses. Seminars in Oncology, 2010, 37, 649-661. | 0.8 | 19 |
| 100 | Seladin-1 expression is regulated by promoter methylation in adrenal cancer. BMC Cancer, 2010, 10, 201. | 1.1 | 12 |
| 101 | Within-Patient Reproducibility of the Aldosterone:Renin Ratio in Primary Aldosteronism. Hypertension, 2010, 55, 83-89. | 1.3 | 70 |
| 102 | Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocrine-Related Cancer, 2010, 18, 97-111. | 1.6 | 169 |
| 103 | Pheochromocytoma in rats with multiple endocrine neoplasia (MENX) shares gene expression patterns with human pheochromocytoma. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18493-18498. | 3.3 | 36 |
| 104 | Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model. Endocrine-Related Cancer, 2010, 17, 169-177. | 1.6 | 32 |
| 105 | Role of the PPAR-Î³ System in Normal and Tumoral Pituitary Corticotropic Cells and Adrenal Cells. Neuroendocrinology, 2010, 92, 23-27. | 1.2 | 19 |
| 106 | Progress in Primary Aldosteronism: Present Challenges and Perspectives. Hormone and Metabolic Research, 2010, 42, 374-381. | 0.7 | 49 |
| 107 | Low Sensitivity of Glucagon Provocative Testing for Diagnosis of Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 238-245. | 1.8 | 27 |
| 108 | Il dosaggio delle metanefrine nella diagnosi del feocromocitoma: vantaggi clinici e problematiche di laboratorio. L Endocrinologo, 2010, 11, 65-74. | 0.0 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Spectrum and Prevalence of FP/TMEM127 Gene Mutations in Pheochromocytomas and Paragangliomas. JAMA - Journal of the American Medical Association, 2010, 304, 2611. | 3.8 | 174 |
| 110 | Clinically Guided Genetic Screening in a Large Cohort of Italian Patients with Pheochromocytomas and/or Functional or Nonfunctional Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1541-1547. | 1.8 | 284 |
| 111 | Functional study in a yeast model of a novel succinate dehydrogenase subunit B gene germline missense mutation (C191Y) diagnosed in a patient affected by a glomus tumor. Human Molecular Genetics, 2009, 18, 1860-1868. | 1.4 | 60 |
| 112 | Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocrine-Related Cancer, 2009, 16, 391-400. | 1.6 | 117 |
| 113 | Sindromi feocromocitoma/paraganglioma familiari. L Endocrinologo, 2009, 10, 26-31. | 0.0 | 0 |
| 114 | Biochemistry, genetics and therapy of malignant pheochromocytomas. Annales D'Endocrinologie, 2009, 70, 166-167. | 0.6 | 3 |
| 115 | An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncology, The, 2009, 10, 764-771. | 5.1 | 477 |
| 116 | Uncommon clinical presentations of pheochromocytoma and paraganglioma in two different patients affected by two distinct novel VHL germline mutations. Clinical Endocrinology, 2008, 68, 762-768. | 1.2 | 24 |
| 117 | The Y606C RET mutation causes a receptor gain of function. Clinical Endocrinology, 2008, 69, 253-258. | 1.2 | 16 |
| 118 | Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma. American Journal of Physiology - Endocrinology and Metabolism, 2008, 295, E1223-E1233. | 1.8 | 66 |
| 119 | Body Mass Index Predicts Plasma Aldosterone Concentrations in Overweight-Obese Primary Hypertensive Patients. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2566-2571. | 1.8 | 171 |
| 120 | Rosiglitazone Inhibits Adrenocortical Cancer Cell Proliferation by Interfering with the IGF-IR Intracellular Signaling. PPAR Research, 2008, 2008, 1-11. | 1.1 | 47 |
| 121 | Comparison of the Captopril and the Saline Infusion Test for Excluding Aldosterone-Producing Adenoma. Hypertension, 2007, 50, 424-431. | 1.3 | 142 |
| 122 | A case of hyponatremia caused by central hypocortisolism. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 369-375. | 2.9 | 9 |
| 123 | Genetics and Biology of Pheochromocytoma. Experimental and Clinical Endocrinology and Diabetes, 2007, 115, 160-165. | 0.6 | 23 |
| 124 | Mapping of Human Autoantibody Epitopes on Aromaticl-Amino Acid Decarboxylase. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1096-1105. | 1.8 | 4 |
| 125 | GermlineNF1Mutational Spectra and Loss-of-Heterozygosity Analyses in Patients with Pheochromocytoma and Neurofibromatosis Type 1. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2784-2792. | 1.8 | 126 |
| 126 | Genetic screening for pheochromocytoma: should SDHC gene analysis be included?. Journal of Medical Genetics, 2007, 44, 586-587. | 1.5 | 86 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. Journal of Hypertension, 2007, 25, 1433-1442. | 0.3 | 90 |
| 128 | Adjuvant Mitotane Treatment for Adrenocortical Carcinoma. New England Journal of Medicine, 2007, 356, 2372-2380. | 13.9 | 679 |
| 129 | Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 92-102. | 2.9 | 581 |
| 130 | A Prospective Study of the Prevalence of Primary Aldosteronism in 1,125 Hypertensive Patients. Journal of the American College of Cardiology, 2006, 48, 2293-2300. | 1.2 | 1,236 |
| 131 | Renal Damage in Primary Aldosteronism. Hypertension, 2006, 48, 232-238. | 1.3 | 424 |
| 132 | Phaeochromocytoma, new genes and screening strategies. Clinical Endocrinology, 2006, 65, 699-705. | 1.2 | 130 |
| 133 | SDH Mutations in Patients Affected by Paraganglioma Syndromes: A Personal Experience. Annals of the New York Academy of Sciences, 2006, 1073, 183-189. | 1.8 | 10 |
| 134 | Management and Treatment of Pheochromocytomas and Paragangliomas. Annals of the New York Academy of Sciences, 2006, 1073, 405-416. | 1.8 | 64 |
| 135 | Gene Expression Profiling of Benign and Malignant Pheochromocytoma. Annals of the New York Academy of Sciences, 2006, 1073, 541-556. | 1.8 | 59 |
| 136 | Pheochromocytoma Catecholamine Phenotypes and Prediction of Tumor Size and Location by Use of Plasma Free Metanephrines. Clinical Chemistry, 2005, 51, 735-744. | 1.5 | 177 |
| 137 | Thiazolidinediones Inhibit Growth and Invasiveness of the Human Adrenocortical Cancer Cell Line H295R. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1332-1339. | 1.8 | 68 |
| 138 | Elevated Serum Interferon-Î³-Inducible Chemokine-10/CXC Chemokine Ligand-10 in Autoimmune Primary Adrenal Insufficiency andin VitroExpression in Human Adrenal Cells Primary Cultures after Stimulation with Proinflammatory Cytokines. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2357-2363. | 1.8 | 66 |
| 139 | Adrenal Incidentaloma: The Influence of a Decision-Making Algorithm on the Short-Term Outcome of Laparoscopy. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2005, 15, 451-459. | 0.5 | 8 |
| 140 | Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. European Journal of Endocrinology, 2005, 153, 307-315. | 1.9 | 86 |
| 141 | Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma. Endocrine-Related Cancer, 2005, 12, 263-272. | 1.6 | 47 |
| 142 | Phaeochromocytoma. Lancet, The, 2005, 366, 665-675. | 6.3 | 1,462 |
| 143 | Expression of the Novel Adrenocorticotropin-Responsive Gene Selective Alzheimerâ€™s Disease Indicator-1 in the Normal Adrenal Cortex and in Adrenocortical Adenomas and Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1332-1339. | 1.8 | 46 |
| 144 | Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippelâ€“Lindau syndrome. Endocrine-Related Cancer, 2004, 11, 897-911. | 1.6 | 184 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Cushingâ€™s Syndrome in a Patient with Bilateral Macronodular Adrenal Hyperplasia Responding to Cisapride: An in Vivo and in Vitro Study. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4616-4622. | 1.8 | 41 |
| 146 | SPECT semiquantitative analysis of adrenocortical (131)I-6 beta iodomethyl-norcholesterol uptake to discriminate subclinical and preclinical functioning adrenal incidentaloma. Journal of Nuclear Medicine, 2003, 44, 1057-64. | 2.8 | 22 |
| 147 | Biochemical Diagnosis of Pheochromocytoma. JAMA - Journal of the American Medical Association, 2002, 287, 1427-34. | 3.8 | 994 |
| 148 | Handgrip-induced airway dilation in asthmatic patients with bronchoconstriction induced by MCh inhalation. Journal of Applied Physiology, 2002, 93, 1723-1730. | 1.2 | 13 |
| 149 | CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5658-5671. | 1.8 | 1,782 |
| 150 | Adrenal masses in neoplastic patients. Surgical Endoscopy and Other Interventional Techniques, 2001, 15, 90-93. | 1.3 | 61 |
| 151 | Centrally Mediated Effects of Bromocriptine on Cardiac Sympathovagal Balance. Hypertension, 2001, 38, 123-129. | 1.3 | 23 |
| 152 | Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1999-2008. | 1.8 | 262 |
| 153 | Variable Expression of the Transcription Factors cAMP Response Element-Binding Protein and Inducible cAMP Early Repressor in the Normal Adrenal Cortex and in Adrenocortical Adenomas and Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5443-5449. | 1.8 | 22 |
| 154 | Telomerase Activity Is Significantly Enhanced in Malignant Adrenocortical Tumors in Comparison to Benign Adrenocortical Adenomas. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 468-470. | 1.8 | 31 |
| 155 | In Vivo Evidence That Endogenous Dopamine Modulates Sympathetic Activity in Man. Hypertension, 1999, 34, 398-402. | 1.3 | 45 |
| 156 | Angiotensin II Stimulates the Synthesis and Secretion of Vascular Permeability Factor/Vascular Endothelial Growth Factor in Human Mesangial Cells. Journal of the American Society of Nephrology: JASN, 1999, 10, 245-255. | 3.0 | 131 |
| 157 | Effects of clonidine on power spectral analysis of heart rate variability in mild essential hypertension. Journal of the Autonomic Nervous System, 1998, 74, 152-159. | 1.9 | 17 |
| 158 | Low-Dose C-Type Natriuretic Peptide Does Not Affect Cardiac and Renal Function in Humans. Hypertension, 1998, 31, 802-808. | 1.3 | 45 |
| 159 | Effects of acute clonidine administration on power spectral analysis of heart rate variability in healthy humans. Autonomic and Autacoid Pharmacology, 1998, 18, 307-312. | 0.7 | 16 |
| 160 | Pheochromocytoma Crisis Caused by Contemporary Ergotamine, Caffeine, and Nimesulide Administration. American Journal of the Medical Sciences, 1997, 314, 396-398. | 0.4 | 12 |
| 161 | Urinary Endothelin-1 Excretion Is Enhanced by Low-Dose Infusion of Brain Natriuretic Peptide in Normal Humans. Hypertension, 1997, 29, 70-74. | 1.3 | 5 |
| 162 | Impaired cardiovascular autonomic response to passive tilting in cirrhosis with ascites. Hepatology, 1996, 24, 1063-1067. | 3.6 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Systemic hemodynamics and renal function during brain natriuretic peptide infusion in patients with essential hypertension*. American Journal of Hypertension, 1995, 8, 799-807. | 1.0 | 18 |
| 164 | Role for Endogenous Dopamine in Modulating Sympathetic-Adrenal Activity in Humans. Hypertension Research, 1995, 18, S79-S86. | 1.5 | 6 |
| 165 | A further case of giant intrasellar carotid aneurysm mimicking a pituitary adenoma: The relevance of a multivariate approach in differential diagnosis. Italian Journal of Neurological Sciences, 1994, 15, 369-372. | 0.1 | 7 |
| 166 | Bilateral massive adrenal hemorrhage due to sepsis: Report of two cases. Journal of Endocrinological Investigation, 1994, 17, 821-824. | 1.8 | 20 |
| 167 | Adrenal medulla secretion in Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism, 1994, 78, 1331-1335. | 1.8 | 7 |
| 168 | Dopamine D2 receptor gene expression and binding sites in adrenal medulla and pheochromocytoma [published erratum appears in J Clin Endocrinol Metab 1994 Oct;79(4):1165]. Journal of Clinical Endocrinology and Metabolism, 1994, 79, 56-61. | 1.8 | 22 |
| 169 | Frequent RET protooncogene mutations in multiple endocrine neoplasia type 2A. Journal of Clinical Endocrinology and Metabolism, 1994, 79, 590-594. | 1.8 | 21 |
| 170 | Renal effects of atrial natriuretic peptide during dopa-decarboxylase inhibition in patients with essential hypertension. European Journal of Clinical Pharmacology, 1993, 44, 423-427. | 0.8 | 0 |
| 171 | Impaired cerebral autoregulation in patients with shy-drager syndrome. International Journal of Angiology, 1993, 2, 12-15. | 0.2 | 1 |
| 172 | A nonsecreting pheochromocytoma presenting as an incidental adrenal mass. Report on a case. Journal of Endocrinological Investigation, 1993, 16, 817-822. | 1.8 | 24 |
| 173 | Dopamine Modulation of Pathological Human Chromaffin Tissue. American Journal of Hypertension, 1990, 3, 22S-24S. | 1.0 | 3 |
| 174 | Regional Differences of Adenylate Cyclase Stimulation by Calcitonin and Calcitonin Gene-Related Peptide in the Human Kidney*. Journal of Clinical Endocrinology and Metabolism, 1989, 69, 491-495. | 1.8 | 10 |
| 175 | Diagnostic problems in pheochromocytoma. Journal of Endocrinological Investigation, 1989, 12, 739-757. | 1.8 | 25 |
| 176 | Presence of dopamine-dependent adenylate cyclase activity in human renal cortex. European Journal of Pharmacology, 1988, 149, 351-356. | 1.7 | 17 |
| 177 | Measurement of catecholamines, met-enkephalin, somatostatin and substance P-like immunoreactivities in 12 human pheochromocytomas. Journal of Endocrinological Investigation, 1988, 11, 133-138. | 1.8 | 8 |
| 178 | Endogenous Dopamine (DA) and DA2 Receptors: A Mechanism Limiting Excessive Sympathetic-Adrenal Discharge in Humans*. Journal of Clinical Endocrinology and Metabolism, 1988, 66, 626-631. | 1.8 | 49 |
| 179 | Usefulness of basal catecholamine plasma levels and clonidine suppression test in the diagnosis of pheochromocytoma. Journal of Endocrinological Investigation, 1987, 10, 377-382. | 1.8 | 20 |
| 180 | Opioid Modulation of Normal and Pathological Human Chromaffin Tissue*. Journal of Clinical Endocrinology and Metabolism, 1986, 62, 577-582. | 1.8 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Does endogenous dopamine modulate human sympathetic activity through DA2 receptors?. European Journal of Clinical Pharmacology, 1985, 29, 159-164. | 0.8 | 17 |
| 182 | Naloxone administration does not affect gonadotrophin secretion in male patients with isolated hypogonadotrophic hypogonadism. European Journal of Endocrinology, 1985, 109, 153-157. | 1.9 | 4 |
| 183 | Effects of naloxone on catecholamine plasma levels in adult men. A dose-response study. European Journal of Endocrinology, 1984, 106, 357-361. | 1.9 | 19 |
| 184 | Effects of Different Dopaminergic Antagonists on Bromocriptine-Induced Inhibition of Norepinephrine Release*. Journal of Clinical Endocrinology and Metabolism, 1984, 59, 74-78. | 1.8 | 36 |
| 185 | Vasoactive factors in the mechanism of renal sodium handling in cirrhotics: The effect of acute plasma expansion. Pharmacological Research Communications, 1984, 16, 613-635. | 0.2 | 1 |
| 186 | Effects of thyroid replacement therapy on catecholamine plasma levels. Journal of Endocrinological Investigation, 1983, 6, 307-309. | 1.8 | 8 |
| 187 | A study on human adrenal secretion. Measurement of epinephrine, norepinephrine, dopamine and Cortisol in peripheral and adrenal venous blood under surgical stress. Journal of Endocrinological Investigation, 1982, 5, 91-95. | 1.8 | 30 |
| 188 | Klinefelterâ€™s syndrome: a study of its hormonal plasma pattern. Journal of Endocrinological Investigation, 1978, 1, 149-154. | 1.8 | 25 |
| 189 | Klinefelterâ€™s syndrome: effects of short-term testosterone administration on hypothalamic-pituitary axis function. Journal of Endocrinological Investigation, 1978, 1, 239-244. | 1.8 | 4 |